Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/10/2019
Start Date:February 28, 2018
End Date:December 2024
Contact:Iovance Biotherapeutics Clinical Inquiries
Email:clinical.inquiries@iovance.com
Phone:866-565-4410

Use our guide to learn which trials are right for you!

A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combination With Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study is a Phase 2, open-label, multicenter study evaluating adoptive cell therapy (ACT)
with autologous TIL therapy (LN-145) in combination with Anti-PD-L1 inhibitor durvalumab.

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing
process, as originally developed by the NCI. The cell transfer therapy used in this study
involves patients receiving a nonmyeloablative (NMA) lymphocyte depleting preparative
regimen, followed by infusion of autologous TIL followed by the administration of a regimen
of IL-2.

Inclusion Criteria:

- Confirmed diagnosis of Stage III or Stage IV NSCLC and progressed after ≤ 3 lines of
prior systemic therapy in the locally advanced or metastatic setting

- Have at least 1 lesion resectable for TIL generation

- Measurable disease as defined by RECIST v1.1

- Male or female, ≥ 18 years of age

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and estimated
life expectancy of ≥ 3 months

- Adequate bone marrow function at screening

- Adequate organ function at screening

- A washout period from prior anticancer therapy(ies) of a minimum duration is required
prior to first study treatment

- Recovered from all prior anticancer therapy-related AEs to Grade 1 or less (per CTCAE
v4.03) prior to enrollment

- Female patients of childbearing potential and male patients with partners of
childbearing potential patient must agree to use contraception while on study and
during the timeframes as specified following the last dose of study drug(s) received,
or until the first dose of the subsequent anticancer therapy, whichever is longer

- Evidence of postmenopausal status or negative urine or serum pregnancy test for female
premenopausal patients

Exclusion Criteria:

- History of other malignancies, except for the following: adequately treated
nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix,
curatively-treated thyroid cancer, or other solid tumors curatively treated with no
evidence of disease for ≥ 3 years

- Patients who have received prior cell therapy

- Patients who have received prior checkpoint inhibitors: such as anti-PD-1, anti-PD-L1
inhibitors, and durvalumab

- Active or prior documented autoimmune or inflammatory disorders

- History of primary or acquired immunodeficiency syndrome, history of allogeneic organ
transplant that requires therapeutic immunosuppression

- Received live or attenuated vaccination within 28 days prior to the start of NMA-LD

- Patients with a history of hypersensitivity to any component of the study drugs

- Mean QT interval ≥ 470 msec

- Patients who have a left ventricular ejection fraction (LVEF) of < 45% or who are New
York Heart Association (NYHA) Class 2 or higher

- Serious illnesses or medical conditions, which would pose increased risk for study
participation and/or compliance with the protocol

- Patients who have obstructive or restrictive pulmonary disease and have a documented
FEV1 (forced expiratory volume in 1 second) of ≤ 60%

- Active central nervous system metastases and/or leptomeningeal disease

- Female patients who are pregnant or breastfeeding

- Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or HIV

- Current or prior use of immunosuppressive medication within 28 days before the first
dose of study treatment, with the exceptions of intranasal and inhaled corticosteroids
or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day
of prednisone, or an equivalent corticosteroid
We found this trial at
8
sites
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials